Snake venom neurotoxin (SVN)

Snake venom neurotoxins represent a diverse group of proteins and peptides secreted by venomous snakes, primarily those in the Elapidae and Viperidae families. These toxins are highly specialized to disrupt the host's nervous system, leading to rapid immobilization or death of prey. Their primary mechanism of action involves the highly specific targeting of critical components in the peripheral nervous system, such as nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction or various voltage-gated ion channels. In clinical settings, these neurotoxins are the principal cause of life-threatening paralysis and respiratory failure following a snakebite. From a therapeutic perspective, snake venom neurotoxins are the primary targets for antivenom therapies, which utilize polyclonal antibodies to neutralize the circulating toxins. Beyond their role in envenomation, these molecules are significant in drug discovery due to their extreme potency and selectivity; for instance, they serve as templates for developing novel analgesics or treatments for neurological disorders. Research into small-molecule inhibitors, such as those targeting phospholipase A2 neurotoxins, represents a modern approach to supplement traditional antibody-based antivenoms. Their clinical relevance is defined by the narrow therapeutic window available for neutralization before irreversible physiological damage occurs.

Other names

Three-finger toxins3FTxsAlpha-neurotoxinsBeta-neurotoxinsDendrotoxinsFasciculinsMuscarinic toxinsPhospholipase A2 neurotoxinsPresynaptic neurotoxinsPostsynaptic neurotoxins

Antivenoms and neutralizing agents function by binding to the neurotoxins to form inactive complexes, preventing the toxins from reaching or binding to their physiological targets such as nicotinic acetylcholine receptors or voltage-gated ion channels. Small molecule inhibitors like Varespladib specifically inhibit the enzymatic activity of secreted phospholipase A2 neurotoxins, while acetylcholinesterase inhibitors like neostigmine provide symptomatic relief by increasing acetylcholine concentrations at the synaptic cleft to compete with postsynaptic neurotoxins.